Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2008
by The Hospital for Sick Children.
Recruitment status was Recruiting
Study NCT00376077 Information provided by The Hospital for Sick Children
First Received on September 12, 2006. Last Updated on January 10, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Immune Thrombocytopenic Purpura
Additional conditions recognized in this trial
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
More general conditions related to this trial
Autoimmune Diseases
Blood Coagulation Disorders
Blood Platelet Disorders
Hematologic Diseases
Hemorrhage
Hemorrhagic Disorders
Immune System Diseases
Pathologic Processes
Signs and Symptoms
Skin Manifestations
Thrombocytopenia
Thrombotic Microangiopathies
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Rho(D) Immune Globulin
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Autonomic Agents
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
The Hospital for Sick Children
Bayer
Back to top of Main Content